Though pharma and life sciences companies are more resilient to this crisis than many, they’re not immune to the economic challenges and events arising from COVID-19.
Like other businesses within the broader healthcare ecosystem, they face the unique challenge of ensuring their own operational health, while coping with soaring demand for treatments and therapies.
Many are being forced to stray from tried-and-tested operating models, but the challenges today may well help to create strong structures for the future.
Our experts discuss how this period will be transformative for the pharma and broader life sciences sector and why agility, innovation and collaboration will be absolutely critical to success.
“For pharma companies that have had to contest with a mixed public reputation in recent years, this is an opportunity to prove how instrumental they can be in creating a stronger and fairer health system.”
This insight is brought to you using the capability of Strategy&, PwC’s global strategy house, alongside our PwC industry experts. Together, we transform organisations by developing actionable strategies that deliver results.
We are uniquely placed to combine strategy with technical, industry and execution expertise. We embed our strategy capabilities with expert teams across our PwC network, to show you where you need to go, the choices you’ll need to make to get there, and how to get it right.
The result is an authentic strategy process powerful enough to capture possibility, while pragmatic enough to ensure effective delivery. It’s the strategy that turns vision into reality. It’s strategy, made real.